Patent ID: 11971402
Assignee: CORNELL UNIVERSITY
Field: Measurement (Instruments)
Classification: CPC G  C  Y | IPC C  G

Claim 12:
13. A method of treating a subject having cancer that has metastasized to the brain, lung, or liver, or having cancer that is at risk of metastasizing to the brain, lung, or liver, said method comprising:
selecting a subject having cancer;
obtaining, from the selected subject, a sample containing exosomes;
contacting the exosomes with one or more reagents suitable to determine expression levels, on said exosomes, of one or more of the integrin groups selected from the group consisting of a brain specific group of integrins comprising ITGαv and/or ITGβ3; a lung specific group of integrins comprising ITGα6, ITGβ1, and/or ITGβ4; and a liver specific group of integrins comprising ITGαv and/or ITGβ5;
detecting (A) an increase in the expression levels of the selected one or more integrin groups on said exosomes relative to (i) the average expression levels of the selected one or more integrin groups in a non-cancerous exosomal sample; (ii) the average expression levels of the selected one or more integrin groups in a non-metastatic cancerous exosomal sample; (iii) the expression levels of the selected one or more integrin groups in an exosomal sample taken from the selected subject at an earlier time point; or (B) no change in the expression levels of the selected one or more integrin groups on said exosomes relative to the average expression level of the selected one or more integrin groups in a metastatic cancerous exosomal sample;
prognosing that the cancer is likely to metastasize to a site selected from the group consisting of the brain, the lung, and the liver, respectively, based on said detecting the brain specific group, the lung specific group, and the liver specific group of integrins;
selecting a therapeutic integrin inhibitor based on said detecting; and
administering to the selected subject (i) an inhibitor of ITGαv and/or ITGβ3 as the therapeutic integrin inhibitor when the subject has an exosomal integrin profile indicative of brain metastasis; (ii) an inhibitor of ITGα6, ITGβ1, and/or ITGβ4 as the therapeutic integrin inhibitor when the subject has an exosomal integrin profile indicative of lung metastasis; and (iii) an inhibitor of ITGαv and/or ITGβ5 as the therapeutic integrin inhibitor when the subject has an exosomal integrin profile indicative of liver metastasis, in order to treat the cancer.